J.P. Morgan Healthcare Conference 2026: Navigating New Therapeutic Frontiers
Executive Summary
The upcoming J.P.
Morgan Healthcare Conference is expected to shift focus from modality hype (like GLP-1s) to clinical validation of new mechanisms of action across the industry.
The speaker is highly bullish on targeted protein degradation, citing recent positive data and its potential to become an entirely new class of drugs for oncology and immunology.
Gene editing and gene writing are identified as foundational future technologies, with tissue-specific delivery beyond the liver being the critical challenge to unlock their full potential.
CAR-T cell therapies are poised for significant expansion beyond oncology into immunological and autoimmune diseases, with in vivo approaches seen as key to improving scalability and accessibility.
7 quotes
Concerns Raised
Achieving tissue-specific drug delivery beyond the liver for genetic medicines.
Current scalability and accessibility limitations of ex vivo cell therapies.
Opportunities Identified
Targeted protein degradation emerging as a completely new class of drugs.
Expansion of CAR-T therapies into the large autoimmune and immunological disease markets.
In vivo CAR-T approaches dramatically improving the scalability and accessibility of cell therapy.
Gene editing and writing becoming foundational capabilities for the entire industry.